reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Wim Lewi
- Jacob Mekhael
Galapagos Media reports Paul Stoffels behind non-binding offer for cel...
According to media reports, Paul Stoffels, Galapagos' previous CEO, has assembled a group of investors to bid for the company's cell therapy business. After joining Galapagos in 2022, Paul Stoffels pivoted the company towards cell therapies and focussed the company's efforts on de-centralised CAR-T manufacturing as a way to broaden access to such treatments. Following his resignation earlier this year, he now has placed a non-binding offer for the cell therapy business which is under strategic r...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
Galapagos Receives non-binding offers for cell therapy business
Galapagos announced that it has received a limited number of non-binding offers from consortia, predominantly comprised of financial investors, to acquire the cell therapy business. The deadline for potential bidders to put forward binding, fully-financed, offers is in the coming weeks. The company will make an announcement on the outcome of the review of strategic alternatives for the cell therapy business no later than its 3Q25 update on 5 November 2025. € 37 TP and ACCUMULATE reiterated.
Galapagos Provides Update on Strategic Alternatives for Its Cell Thera...
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement: On May 13, 2025, Galapagos announced that its Board of Directors (the “Board”) had decided to explore all strategic alternatives for its cell therapy business (the “Cell Therapy Business”), including a potential divestiture of the Cell Therapy Business, with the goal of preserving shareholder value. As part of its review of strategic alternatives, over ...
Galapagos geeft update over strategische alternatieven voor haar celth...
Galapagos geeft update over strategische alternatieven voor haar celtherapieactiviteiten Mechelen, België; 1 oktober 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) en haar Raad van Bestuur hebben vandaag de volgende verklaring uitgegeven: Op 13 mei 2025 kondigde Galapagos aan dat haar Raad van Bestuur (de “Raad”) had besloten om alle strategische alternatieven voor haar celtherapieactiviteiten (de “Celtherapieactiviteiten”) te verkennen, met inbegrip van een mogelijke verkoop van de Celtherapieactiviteiten, met als doel het waarborgen van aandeelhouderswaarde. Als onderdeel...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Wim Lewi
Corbion reports the progress of its share buyback program 22 September...
Corbion reports the progress of its share buyback program 22 September – 26 September 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 22 September up to and including 26 September 2025 a total of 57.112 shares were repurchased at an average price of €16.756 for a total amount of €956,979.58 To date, the total consideration for shares repurchased amounts to €3,551,493.30 representing 35.51% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the pro...
- ING Helpdesk
Benelux Morning Notes
Belgian telecoms: Telenet increases its fixed internet speed at unchanged price Colruyt: FY25/26F profitability guidance maintained despite market share loss Corbion: Keep Calm and Carry On Fagron: Acquires UCP, adding to its 503A health and wellness offering in California GBL: Planning ahead to deliver on its promise OCI: Limited details on Orascom merger, sales process for Nitrogen Europe ongoing TKH Group: Mixed emotions Wolters Kluwer: Launches UpToDate Expert AI
Corbion reports the progress of its share buyback program 15 September...
Corbion reports the progress of its share buyback program 15 September – 19 September 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 15 September up to and including 19 September 2025 a total of 37.260 shares were repurchased at an average price of €17.0780 for a total amount of €636,327.91 To date, the total consideration for shares repurchased amounts to €2,594,512.93 representing 25.95% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the pr...
- Guy Sips
- Hilde Van Boxstael
- Livio Luyten
- Michiel Declercq
- Wim Hoste
- Wim Lewi
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
OSE OSE IMMUNOTHERAPEUTICS SA
RI PERNOD RICARD SA
HO THALES SA
RCO REMY COINTREAU SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ISP INTESA SANPAOLO S.P.A.
GNFT GENFIT SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
MEDCL MEDINCELL SA
CPR DAVIDE CAMPARI-MILANO N.V.
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
OSE OSE IMMUNOTHERAPEUTICS SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
ALDEL DELFINGEN INDUSTRY SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
GBT GUERBET SA
GOE GROUPE GORGE SA
ISP INTESA SANPAOLO S.P.A.
TIETO TIETOEVRY OYJ
GNFT GENFIT SA
SESL SES-IMAGOTAG SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
FLU FLUGHAFEN WIEN AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
UPG UNIFIEDPOST GROUP
ECMPA EUROCOMMERCIAL PROPERTIES NV
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
OSE OSE IMMUNOTHERAPEUTICS SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
ALDEL DELFINGEN INDUSTRY SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
GBT GUERBET SA
GOE GROUPE GORGE SA
ISP INTESA SANPAOLO S.P.A.
TIETO TIETOEVRY OYJ
GNFT GENFIT SA
SESL SES-IMAGOTAG SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
FLU FLUGHAFEN WIEN AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
UPG UNIFIEDPOST GROUP
ECMPA EUROCOMMERCIAL PROPERTIES NV
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
OSE OSE IMMUNOTHERAPEUTICS SA
RI PERNOD RICARD SA
HO THALES SA
RCO REMY COINTREAU SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ISP INTESA SANPAOLO S.P.A.
GNFT GENFIT SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
MEDCL MEDINCELL SA
CPR DAVIDE CAMPARI-MILANO N.V.
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
- Team Pharma
EVT EVOTEC SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
- Team Pharma
EVT EVOTEC SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
Corbion reports the progress of its share buyback program 8 September ...
Corbion reports the progress of its share buyback program 8 September – 12 September 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 8 September up to and including 12 September 2025 a total of 28.805 shares were repurchased at an average price of €17.4190 for a total amount of €501,753.53 To date, the total consideration for shares repurchased amounts to €1,985,185.01 representing 19.58% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the prog...
- ING Helpdesk
Benelux Morning Notes
Ageas: Highlights ING Benelux Conference London. Alfen: Highlights from ING Benelux Conference London. Arcadis: Highlights ING Benelux Conference London. ASR: Highlights ING Benelux Conference London. BAM: Highlights ING Benelux Conference London. Basic-Fit: Highlights ING Benelux Conference London. CTP: Highlights from ING Benelux Conference London. DEME Group: Highlights ING Benelux Conference London. Fugro: Highlights ING Benelux Conference London. Heijmans: Highlights ING Bene...
SBMO SBM OFFSHORE NV
AGS AGEAS SA/NV
RAND RANDSTAD NV
PNL POSTNL NV
BAMNB KONINKLIJKE BAM GROEP NV
LOTB LOTUS BAKERIES NV
HEIJM HEIJMANS N.V. CERT
ARCAD
ARCADIS NV
ASRNL ROYAL VOPAK NV
TWEKA ASR NEDERLAND NV
ALFEN TKH GROUP N.V. CERT
FUR ALFEN NV
CTPNV FUGRO NV
DEME CTP NV
DEME GROUP NV
Corbion reports the progress of its € 10 million share buyback program...
Corbion reports the progress of its € 10 million share buyback program 1 September – 5 September 2025 Corbion hereby reports the transaction details related to its € 10 million share buyback program announced on 1 September 2025. During the week of 1 September up to and including 5 September 2025 a total of 83,962 shares were repurchased at an average price of €17.3463 for a total amount of €1,456,431.48. To date, the total consideration for shares repurchased amounts to €1,456,431.48 representing 14.56% of the overall share buyback program. Corbion publishes on a weekly basis every Mond...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.